midodrine

(redirected from ProAmatine)
Also found in: Medical.
Related to ProAmatine: Midodrine, Midodrine hydrochloride
Translations

midodrine

n midodrina
References in periodicals archive ?
Shire has no financial interest in midodrine, and no longer manufactures, distributes or markets the brand name version of midodrine HCI, ProAmatine.
Midodrine received accelerated approval as ProAmatine in 1996 based on the surrogate end point of increase in 1-minute standing systolic blood pressure.
The Irish drugmaker said in a statement it will withdraw ProAmatine by the end of September.
22, 2011 /PRNewswire/ -- Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, announces an update on the approval status and availability of ProAmatine (midodrine HCl), a medicine approved for the treatment of symptomatic orthostatic hypotension (SOH).
PHILADELPHIA, September 13, 2010 /PRNewswire/ -- Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, announces that the United States Food and Drug Administration today posted an update on its website related to ProAmatine (known generically as midodrine), a medicine approved for the treatment of symptomatic orthostatic hypotension.
Shire Pharmaceuticals Group plc (Nasdaq:SHPGY) markets PROAMATINE for treatment of symptomatic orthostatic hypotension.
PHILADELPHIA, Pennsylvania, August 17, 2010 /PRNewswire/ -- Shire plc (LSE: SHP, NASDAQ: SHPGY) acquired ProAmatine as a part of the acquisition of Roberts Pharma in 1999 and Shire conducted and completed the post marketing trials that the FDA required.
The drug, marketed as ProAmatine by Shire Development Inc.
impact of generic competition on PROAMATINE sales and comparison to a high base
Growth was depressed by a full quarter's impact of generic competition on PROAMATINE sales and comparison to a high base quarter in Q1 2003, which included high levels of wholesaler inventories.
despite the loss of exclusivity on PROAMATINE in Q3 2003 and the anticipated
For 2004, Shire expects revenue growth to be in the high single digit range, despite the loss of exclusivity on PROAMATINE in Q3 2003 and the anticipated loss of exclusivity on AGRYLIN in the US in Q4 2004.